Azenosertib for Ovarian Cancer

(ASPENOVA Trial)

This trial explores the effectiveness of a new treatment, azenosertib (ZN-c3), compared to standard chemotherapy for ovarian cancer that resists common platinum-based treatments. Researchers focus on patients whose cancer cells exhibit a specific protein marker, cyclin E1. Women with platinum-resistant ovarian cancer who have undergone one to three prior treatments, including bevacizumab and PARP inhibitors, may be suitable candidates. The trial aims to discover a more effective way to manage this challenging cancer type. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering hope for a new, effective option.

The trial protocol mentions that participants must be able to stop taking certain prescription or nonprescription drugs and food or herbal supplements that are prohibited by the study. It doesn't specify which medications, so you should discuss your current medications with the study team to see if any need to be stopped.

Studies have shown that azenosertib (also known as ZN-c3) is generally safe and well-tolerated in people with ovarian cancer. Earlier research found that about 34.9% of patients responded to azenosertib, indicating effectiveness for roughly one-third of them. Azenosertib has also been tested with other drugs like niraparib, focusing on safety. Results suggest that azenosertib does not cause severe side effects for most people.

Most treatments for ovarian cancer, like chemotherapy, work by targeting rapidly dividing cells but can harm healthy cells in the process. Azenosertib is unique because it specifically inhibits the WEE1 kinase, a protein that helps cancer cells repair DNA damage and continue growing. By blocking WEE1, Azenosertib aims to make cancer cells more vulnerable to damage and cell death while potentially sparing healthy cells. Researchers are excited about this targeted approach as it may offer a more effective and less toxic treatment option compared to traditional chemotherapy.

Research has shown that azenosertib holds promise for treating ovarian cancer unresponsive to platinum-based treatments. In earlier studies, about 35% of patients with tumors containing the cyclin E1 protein experienced improvement with azenosertib. This indicates that roughly one in three patients responded positively to the treatment. These patients also had an average period of about 6.5 months without cancer progression. This trial will compare azenosertib, administered in Arm A, with an investigator's choice of chemotherapy in Arm C. Overall, the evidence supports azenosertib as a potentially effective option for this challenging condition.¹²³⁶⁷